Genenta Science S.p.A. — Investor Relations & Filings
Genenta Science is a clinical-stage company developing immuno-oncology therapies based on a proprietary hematopoietic stem cell (HSC) gene therapy platform. The company's technology is designed to reprogram the tumor microenvironment, making solid tumors visible to the immune system and breaking immune tolerance. Its lead candidate, Temferon, aims to deliver therapeutics directly within the tumor mass. The treatment is being investigated as a potential one-time monotherapy and in combination with other approved therapeutics, such as immune checkpoint inhibitors. Clinical development includes a completed Phase 1 trial for Glioblastoma Multiforme and an ongoing Phase 1/2a study in metastatic Renal Cell Carcinoma.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-29 | English | |
| 6-K | 2026-05-19 | English | |
| 6-K - Genenta Science S.p.A. (0001838716) (Filer) | 2026-03-27 | English | |
| 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | |
| 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | |
| 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 47893721 | 6-K | 2026-05-29 | English | ||
| 46559661 | 6-K | 2026-05-19 | English | ||
| 33057481 | 6-K - Genenta Science S.p.A. (0001838716) (Filer) | 2026-03-27 | English | ||
| 32979435 | 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | ||
| 32979131 | 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | ||
| 32979121 | 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | ||
| 32005936 | 6-K Filing | 2026-01-27 | English | ||
| 32005934 | 6-K Filing | 2026-01-27 | English | ||
|
2025
7 filings
| |||||
| 13358583 | 6-K | 2025-11-03 | English | ||
| 13358584 | 424B5 | 2025-10-28 | English | ||
| 13358585 | 6-K | 2025-10-28 | English | ||
| 13358586 | 6-K | 2025-10-27 | English | ||
| 13358590 | 6-K | 2025-10-10 | English | ||
| 13358587 | 6-K | 2025-10-03 | English | ||
| 13358591 | 6-K | 2025-09-10 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Genenta Science S.p.A., but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Jeevan Scientific Technology Limited
A CRO providing Phase I-IV trials, BA/BE research, and phar…
|
538837 | IN | Professional, scientific and te… |
|
J. Molner AS
A CDRO developing generic sterile injectable and dermatolog…
|
JML | EE | Professional, scientific and te… |
|
JOINN Laboratories (China) Co., Ltd.
Comprehensive CRO providing end-to-end preclinical drug dis…
|
6127 | HK | Professional, scientific and te… |
|
JOINN LABORATORIES (CHINA) CO., LTD.
A CRO specializing in non-clinical safety assessment and ph…
|
603127 | CN | Professional, scientific and te… |
|
Kadimastem Ltd.
Clinical-stage cell therapy company developing treatments f…
|
KDST | IL | Professional, scientific and te… |
|
KAINOS MEDICINE, INC.
Develops small molecule therapeutics for neurodegenerative,…
|
284620 | KR | Professional, scientific and te… |
|
Kairos Pharma, LTD.
Develops oncology therapies targeting drug resistance and i…
|
KAPA | US | Professional, scientific and te… |
|
Kancera
Pharmaceutical company seeking a reverse takeover to levera…
|
KAN | SE | Professional, scientific and te… |
|
KAZIA THERAPEUTICS LTD
Oncology-focused biotech developing targeted therapies for …
|
KZIA | US | Professional, scientific and te… |
|
Keros Therapeutics, Inc.
Develops protein therapeutics for disorders linked to TGF-β…
|
KROS | US | Professional, scientific and te… |
Genenta Science S.p.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34499/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34499 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34499 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34499 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34499}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Genenta Science S.p.A. (id: 34499)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.